210 related articles for article (PubMed ID: 14685154)
1. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Hodgkin's disease.
Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
[TBL] [Abstract][Full Text] [Related]
3. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
5. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
6. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
[TBL] [Abstract][Full Text] [Related]
9. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
10. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Epstein-Barr virus-associated cancers.
Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
15. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells and EBV associated malignancies.
Li J; Qian CN; Zeng YX
Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
20. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
